Bionano Genomics (BNGO) awards 10,890-share stock option to PAO

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported an insider equity award to its Principal Accounting Officer, Mark Adamchak. On February 2, 2026, he received a stock option giving him the right to buy 10,890 shares of common stock at an exercise price of $1.27 per share. The option was granted at no cost and is held directly. According to the filing, 100% of the shares subject to the option vest on the one-year anniversary of the grant date, aligning his compensation more closely with the company’s future share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adamchak Mark

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.27	02/02/2026		A		10,890		(1)	02/01/2036	Common Stock	10,890	$0	10,890	D

Explanation of Responses:

1. 100% of the shares subject to the option vest on the one-year anniversary of the grant date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bionano Genomics (BNGO) report for February 2, 2026?

Bionano Genomics reported a stock option grant to Principal Accounting Officer Mark Adamchak on February 2, 2026. He received an option to purchase 10,890 shares of common stock at an exercise price of $1.27 per share, with the award reported as held directly.

Who is Mark Adamchak in the Bionano Genomics (BNGO) Form 4 filing?

The Form 4 identifies Mark Adamchak as an officer of Bionano Genomics, serving as Principal Accounting Officer. The filing shows he is a reporting person under Section 16 and discloses a stock option grant awarded to him, which is held in his direct ownership.

What are the key terms of the 10,890-share stock option granted to Mark Adamchak at Bionano Genomics (BNGO)?

The grant is a stock option giving Mark Adamchak the right to buy 10,890 shares at an exercise price of $1.27 per share. The filing notes the option was granted at a price of $0 for the derivative itself, and it is reported as directly owned.

How many derivative securities does Mark Adamchak own after the reported transaction at Bionano Genomics (BNGO)?

After the transaction, the Form 4 shows Mark Adamchak beneficially owns 10,890 derivative securities, all in the form of a stock option. These represent rights to purchase 10,890 shares of Bionano Genomics common stock, reported as directly held following the grant.

When do the granted stock options to Mark Adamchak at Bionano Genomics (BNGO) vest?

According to the footnote, 100% of the shares subject to the option vest on the one-year anniversary of the grant date. This means all 10,890 option shares become fully vested simultaneously one year after the February 2, 2026 grant.